Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Clinical trial NCT06235918 · UNKNOWN

Trial details

NCT number: NCT06235918
Sponsor: Xiang Lu
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Carcinomas Resectable Head and Neck Squamous-cell Carcinoma

Start date: 2023-01-01
Primary completion: 2025-01-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.